- Home
- GRI vs ZCMD Comparison
GRI vs ZCMD Comparison
Compare GRI & ZCMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GRI
- ZCMD
- Stock Information
- Founded
- GRI 2018
- ZCMD 2012
- Country
- GRI United States
- ZCMD China
- Employees
- GRI N/A
- ZCMD N/A
- Industry
- GRI Biotechnology: Pharmaceutical Preparations
- ZCMD Other Consumer Services
- Sector
- GRI Health Care
- ZCMD Real Estate
- Exchange
- GRI Nasdaq
- ZCMD Nasdaq
- Market Cap
- GRI 3.0M
- ZCMD 3.4M
- IPO Year
- GRI N/A
- ZCMD 2020
- Fundamental
- Price
- GRI $0.77
- ZCMD $1.20
- Analyst Decision
- GRI Strong Buy
- ZCMD
- Analyst Count
- GRI 1
- ZCMD 0
- Target Price
- GRI $12.00
- ZCMD N/A
- AVG Volume (30 Days)
- GRI 9.9M
- ZCMD 15.1K
- Earning Date
- GRI 11-14-2024
- ZCMD 01-01-0001
- Dividend Yield
- GRI N/A
- ZCMD N/A
- EPS Growth
- GRI N/A
- ZCMD N/A
- EPS
- GRI N/A
- ZCMD N/A
- Revenue
- GRI N/A
- ZCMD $17,406,104.00
- Revenue This Year
- GRI N/A
- ZCMD N/A
- Revenue Next Year
- GRI N/A
- ZCMD N/A
- P/E Ratio
- GRI N/A
- ZCMD N/A
- Revenue Growth
- GRI N/A
- ZCMD 1.01
- 52 Week Low
- GRI $0.30
- ZCMD $1.00
- 52 Week High
- GRI $106.29
- ZCMD $9.90
- Technical
- Relative Strength Index (RSI)
- GRI 49.32
- ZCMD 36.47
- Support Level
- GRI $0.79
- ZCMD $1.17
- Resistance Level
- GRI $1.00
- ZCMD $1.28
- Average True Range (ATR)
- GRI 0.17
- ZCMD 0.09
- MACD
- GRI -0.02
- ZCMD -0.00
- Stochastic Oscillator
- GRI 24.95
- ZCMD 6.25
About GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist, for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.
About ZCMD Zhongchao Inc.
ZHONGCHAO Inc is a Cayman Islands-based provider of healthcare information, education, and training services. It provides services to healthcare professionals and the public in China. It offers online and onsite health information services, healthcare education programs, and healthcare training products, consisting of clinical practice training, open classes of popular medical topics, interactive case studies, academic conferences and workshops, continuing education courses, and articles and short videos with educational healthcare content.